NCT00093353 2026-04-14
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
Clinical Trials
108 trialsNCT06095375 2026-01-09
REGOMA-2
Istituto Oncologico Veneto IRCCS
Phase 1 Completed
NCT04474353 2025-12-26
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
Stanford University
Phase 1 Completed
NCT01858168 2025-12-19
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
Massachusetts General Hospital
Phase 1 Completed
NCT03224104 2025-11-26
STEAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT01139970 2025-11-20
Veliparib and Temozolomide in Treating Patients With Acute Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05190315 2025-09-02
Chlorpromazine and Standard of Care in Glioblastoma
University of Iowa
Phase 1 Completed
NCT00629343 2025-06-05
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Columbia University
Phase 1 Completed
NCT00639262 2025-05-02
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
Thomas Jefferson University
Phase 1 Completed
NCT03576612 2025-02-14
GMCI
Candel Therapeutics, Inc.
Phase 1 Completed
NCT02975882 2025-01-14
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT01849146 2025-01-09
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01752491 2024-12-20
A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
University of Iowa
Phase 1 Completed
NCT03150810 2024-12-20
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
Phase 1 Completed
NCT03232424 2024-11-18
NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
Hackensack Meridian Health
Phase 1 Completed
NCT03323034 2024-10-22
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT02193347 2023-12-01
RESIST
Duke University
Phase 1 Completed
NCT03425292 2023-11-08
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
Saint John's Cancer Institute
Phase 1 Completed
NCT00993044 2023-10-06
VIT-B
Children's Hospital Los Angeles
Phase 1 Completed
NCT00138216 2023-10-02
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT00387400 2023-08-04
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
Canadian Cancer Trials Group
Phase 1 Completed
NCT00876993 2023-07-03
Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Johns Hopkins All Children's Hospital
Phase 1 Completed
NCT04541407 2023-05-16
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
University of Colorado, Denver
Phase 1 Completed
NCT04091503 2023-04-25
Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
Center Trials & Treatment Europe
Phase 1 Completed
NCT01269424 2023-03-02
BG & TMZ Therapy of Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 1 Completed
NCT03867123 2023-02-21
A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients
Laminar Pharmaceuticals
Phase 1 Completed
NCT01528046 2023-01-13
Metformin in Children With Relapsed or Refractory Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02311920 2023-01-10
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT02049593 2022-09-26
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT02871843 2022-05-16
G-FORCE-1
EpicentRx, Inc.
Phase 1 Completed
NCT01891747 2022-03-10
A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT02903069 2021-04-19
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Celgene
Phase 1 Completed
NCT00786669 2021-02-10
VITAC
Children's Hospital Medical Center, Cincinnati
Phase 1 Completed
NCT02392793 2021-02-09
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01781403 2021-02-04
Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
Asan Medical Center
Phase 1 Completed
NCT02044120 2021-01-12
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
Sarcoma Alliance for Research through Collaboration
Phase 1 Completed
NCT03139331 2021-01-05
PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
University of California, San Francisco
Phase 1 Completed
NCT01473901 2020-12-09
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Novartis
Phase 1 Completed
NCT01005472 2020-08-03
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT01596140 2020-06-04
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02502708 2020-06-04
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Lumos Pharma
Phase 1 Completed
NCT02378532 2020-01-23
CHLOROBRAIN
Maastricht Radiation Oncology
Phase 1 Completed
NCT00994071 2019-12-09
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02337426 2019-06-28
Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Virginia Commonwealth University
Phase 1 Completed
NCT01480050 2019-05-22
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00892385 2019-02-22
Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00977431 2019-02-18
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
Boehringer Ingelheim
Phase 1 Completed
NCT01576692 2018-11-15
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00527657 2018-11-14
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 1 Completed